


Supplementary Materials

Supplementary Table S1. Design of the four phase 1 studies.



Study [Country]	Study design [n]	Assessments	Comparators	Duration and condition
15L-CL-001 [Japan]	R, DB, dose-escalating study in healthy male volunteers [40]	Safety, PK	Amenamevir capsule 5, 25, 100, 300, or 600 mg Placebo	Single dose administration in a fasting condition
15L-CL-002 [France]	Part 1: R, DB, dose-escalating study in healthy male volunteers [64]	Safety, PK	Amenamevir capsule 5, 25, 100, 300, 600, 1200, 1800, or 2400 mg Placebo	Single dose administration in a fasting condition
	Part 2: R, OL, CO study in healthy male volunteers [8]	Safety, PK, food effect	Amenamevir capsule 300 mg	Single dose administration in a fasting or fed condition
15L-CL-003 [Japan]	R, DB study in healthy non- elderly and elderly male subjects [36]	Safety, PK	Amenamevir capsule 300 or 600 mg Placebo	Dose was administered for 7 days in fed conditions
15L-CL-006 [USA]	R, OL, CO study in healthy male and female subjects [24]	Safety, PK, relative bioavailability, food effect	Amenamevir capsule 800 mg Amenamevir tablet 800 mg	Single dose administration in a fasting or fed condition

CO, crossover, DB, double blind, OL, open label, PK, pharmacokinetics; R, randomized


Supplementary Figure S1. Subject flow of study 15L-CL-001.



Supplementary Figure S2. Subject flow of study 15L-CL-002 (a) Part 1; (b) Part 2.



Supplementary Figure S3. Subject flow of study 15L-CL-003.



Supplementary Figure S4. Subject flow of study 15L-CL-006.

